Effects of N-acetylcysteine on cognitive functions in subjects with an at-risk mental state: A case series

Journal of Clinical Psychopharmacology

Volumn 36, Issue 1, 2016, Pages 87-88

  Miyake, Nobumi ^a   Miyamoto, Seiya ^a   Yamashita, Yusuke ^a   Ninomiya, Yuriko ^a   Tenjin, Tomomi ^a   Yamaguchi, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; SCAVENGER;

COGNITION; FUNCTIONAL STATUS; HIGH RISK PATIENT; HUMAN; LETTER; MENTAL HEALTH; PRIORITY JOURNAL; SCHIZOPHRENIA; ADOLESCENT; ADULT; DRUG EFFECTS; FEMALE; MALE; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

ACETYLCYSTEINE; ADOLESCENT; ADULT; COGNITION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

EID: 84952988727     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000445     Document Type: Letter

References (6)

1. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69:220-229.
2. Liu CC, Demjaha A. Antipsychotic interventions in prodromal psychosis: safety issues. CNS Drugs. 2013;27:197-205.
3. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107-120.
4. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008; 64:361-368.
5. Cabungcal JH, Counotte DS, Lewis EM, et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014;83:1073-1084.
6. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703-715.